Surgical Outcomes Research| Volume 125, ISSUE 2, P217-222, February 1999

The influence of clinical variables on hospital costs after orthotopic liver transplantation


      Background: The burgeoning influence of managed care in transplantation, coupled with a shrinking health-care dollar, has placed most transplant programs under intense pressure to cut costs. We undertook a retrospective cost-identification analysis to determine what clinical variables influenced financial outcomes after orthotopic cadaver liver transplants (OLTx). Methods: Fifty patients receiving 53 transplants between April 1995 and November 1996 were reviewed. Clinical data were obtained from our institution's transplant database, and total costs (not charges) for the transplant admission and the 6 months after transplant were obtained with use of an activity-based cost accounting system (HBOC Trendstar, Atlanta, Ga). Results: The average total cost of second transplants (n = 5) was $97,262 greater than for first transplants (n = 48, P < .05). Patients transplanted initially as United Network for Organ Sharing (UNOS) status 2 (n = 20) incurred average costs that were $51,762 higher than for patients transplanted as UNOS status 3 (n = 28, P = .008). Patients with a major bacterial or fungal infection (n = 28) incurred average costs $46,282 higher than recipients who were infection free (n = 22, P = .02). Multivariate analysis demonstrated that only length of stay, retransplantation, and postoperative dialysis were significantly and independently correlated with costs (r2 = .605). When the model was repeated with preoperative variables alone, only UNOS status was significantly correlated with 6-month total costs (P = .006, r2 = .16). Conclusions: Length of stay is the most important determinant of costs after OLTx. Rational strategies to design cost-effective protocols after OLTx will require further studies to truly define the cost of various morbidities and outcomes after OLTx. (Surgery 1999;125:217-22.)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Finkler SA
        The distinction between costs and charges.
        Arch Intern Med. 1982; 96: 102-109
        • Haley RW
        Measuring the costs of nosocomial infections: methods for estimating economic burden on the hospital.
        Am J Med. 1991; 91: 32S-38S
        • Macario A
        • Vitez TS
        • Dunn B
        • McDonald T
        Where are the costs in perioperative care? Analysis of hospital costs and charges for inpatient surgical care.
        Anesthesiology. 1995; 83: 1138-1144
        • Orloff TM
        • Littell CL
        • Clune C
        • Klingman D
        • Preston B
        Hospital cost accounting: who's doing what and why.
        Health Care Manage Rev. 1990; 15: 73-78
        • Baptist AJ
        A general approach to costing procedures in ancillary departments.
        Top Health Care Fin. 1987; 13: 32-47
        • UNOS
        Graft and patient survival rates.
        in: UNOS 1996 annual report. US Department of Health and Human Services, Washington1997: 144
        • Kim WR
        • Therneau TM
        • Dickson ER
        • Evans RW
        Preoperative predictors of resource utilization in liver transplantation.
        in: Clinical transplants 1995. University of California, Los Angeles, Los Angeles1995: 315-322
        • Brown Jr, RS
        • Ascher NL
        • Lake JR
        • Emond JC
        • Bacchem P
        • Randall HB
        • et al.
        The impact of surgical complications after liver transplantation on resource utilization.
        Ann Surg. 1997; 132: 1098-1103
        • Falagas ME
        • Arbo M
        • Ruthazer R
        • Griffith JL
        • Werner BG
        • Rohrer R
        • et al.
        Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients.
        Transplantation. 1997; 63: 1595-1601
        • Travis JF
        Bottoms up accounting systems: a superior method for controlling health care costs.
        Mod Healthcare. 1977; 17: 50-55
        • Whiting JF
        • Rossi SJ
        • Hanto DW
        Infectious complications after OKT3 induction in liver transplantation.
        Liver Transplant Surg. 1997; 3: 563-570
        • UNOS
        1997 Report of center specific graft and patient survival rates.
        Department of Health and Human Services, Washington1997
        • Powe NR
        • Griffiths RI
        The clinical-economic trial: promise, problems and challenges.
        Controlled Clin Trials. 1995; 16: 377-394
        • Eisenberg JM
        A guide to the economic analysis of clinical practices.
        JAMA. 1989; 262: 2879-2886
        • Mora NP
        • Gonwa TA
        • Goldstein RM
        • Husberg BS
        • Klintmalm GB
        Risk of postoperative infection after liver transplantation: a univariate and stepwise logistic regression analysis of risk factors in 150 consecutive patients.
        Clin Transplantation. 1992; 46: 443-449
        • Bein T
        • Forst H
        • Pratschke E
        Apache-II-scoring in the liver transplant recipient.
        Intensive Care Med. 1997; 18: 60-61
        • Shaw Jr, BW
        • Wood RP
        • Gordon RD
        • Iwatsuki S
        • Gillquist WP
        • Starzl TE
        Influence of selected patient variables and operative blood loss on six-month survival following liver transplantation.
        Semin Liver Dis. 1985; 5: 385-393
        • Evans RW
        A cost-outcome analysis of retransplantation: the need for accountability.
        Transplant Rev. 1993; 7: 163-168
        • Whiting JF
        • Fecteau A
        • Bejarano P
        • Hanto DW
        Use of of low- dose OKT3 as induction therapy in liver transplantation.
        Transplantation. 1998; 65: 577-580
        • Martin JE
        • Fleck P
        • Schroeder TJ
        • Whiting JF
        • Hanto DW
        The cost of rejection in liver allograft recipients.
        Transplant Proc. 1998; 30: 1500-1501
        • Snydman DR
        • Werner BG
        • Dougherty NN
        • Griffith J
        • Rubin RH
        • Dienstag JL
        • et al.
        Cytomegalovirus immune globulin prophylaxis in liver transplantation: a randomized, double-blind, placebo-controlled trial. The Boston Center for Liver Transplantation.
        Ann Intern Med. 1993; 119: 984-991
        • Singh N
        • Yu VL
        • Mieles L
        • Wagener MM
        • Miner RC
        • Miner BA
        • et al.
        High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients.
        Ann Intern Med. 1994; 120: 375-381
        • Winston DJ
        • Wirin D
        • Shaked A
        • Busuttil RW
        Randomized comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients.
        Lancet. 1995; 346: 69-74
        • Patel R
        • Snydman DR
        • Rubin RH
        • Ho M
        • Pescovitz M
        • Martin M
        • et al.
        Cytomegalovirus prophylaxis in solid organ transplant recipients.
        Transplantation. 1996; 61: 1279-1289
        • Hensley KS
        • Lucey MR
        • Normolle DP
        • Merion RM
        • McLaren-Brown KA
        A double-blind, randomized placebo-controlled trial of prostaglandin E1 in liver transplantation.
        Hepatology. 1995; 21: 366-372